Statin Prices Likely To Remain High After Zocor Exclusivity Win
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
You may also be interested in...
Generic Exclusivity On Delisted Patents Upheld By Appeals Court
In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.
Generic Exclusivity On Delisted Patents Upheld By Appeals Court
In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.
Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity
Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.